{
  "subject": "c3ceaafd5738a072103df43c9e62c7c5049265ad67484aba20f898424a3e8a02",
  "claims": [
    {
      "id": "title",
      "proposition": {
        "predicate": "title",
        "object": "Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing"
      },
      "time": {
        "asserted": "2026-11-18T21:09:36.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid",
        "sourceDigest": "sha256:fb91d36264aee08859627c1d71539c3f821c6068c3cda7b5054d11754d39ea11"
      },
      "status": "unverified"
    },
    {
      "id": "summary",
      "proposition": {
        "predicate": "summary",
        "object": "The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of new drug application (NDA) 206679 for Flolipid suspension, 20 milligrams (mg)/5 milliliters (mL) and 40 mg/5 mL and is announcing an opportunity for the NDA holder, Salerno Pharmaceuticals, 2431 East 61st St., Suite 300, Tulsa, OK 74136, to request a hearing on this proposal. The basis for the proposal is that Salerno Pharmaceuticals has repeatedly failed to file required annual reports for NDA 206679."
      },
      "time": {
        "asserted": "2026-11-18T21:09:36.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid",
        "sourceDigest": "sha256:fb91d36264aee08859627c1d71539c3f821c6068c3cda7b5054d11754d39ea11"
      },
      "status": "unverified"
    },
    {
      "id": "url",
      "proposition": {
        "predicate": "url",
        "object": "https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid"
      },
      "time": {
        "asserted": "2026-11-18T21:09:36.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid",
        "sourceDigest": "sha256:fb91d36264aee08859627c1d71539c3f821c6068c3cda7b5054d11754d39ea11"
      },
      "status": "unverified"
    },
    {
      "id": "source-subject",
      "proposition": {
        "predicate": "source-subject",
        "object": "federal-register:2026-23413"
      },
      "time": {
        "asserted": "2026-11-18T21:09:36.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid",
        "sourceDigest": "sha256:fb91d36264aee08859627c1d71539c3f821c6068c3cda7b5054d11754d39ea11"
      },
      "status": "unverified"
    },
    {
      "id": "source-edition",
      "proposition": {
        "predicate": "source-edition",
        "object": "ni:///sha-256;nRIBN7l0iVanJyByrlh3tFc7FUmmNarbfoSRcCioj08"
      },
      "time": {
        "asserted": "2026-11-18T21:09:36.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid",
        "sourceDigest": "sha256:fb91d36264aee08859627c1d71539c3f821c6068c3cda7b5054d11754d39ea11"
      },
      "status": "unverified"
    },
    {
      "id": "source-metadata",
      "proposition": {
        "predicate": "source-metadata",
        "object": {
          "subject": "federal-register:2026-23413",
          "revision": "ni:///sha-256;nRIBN7l0iVanJyByrlh3tFc7FUmmNarbfoSRcCioj08",
          "documentNumber": "2026-23413",
          "documentUrl": "https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid",
          "title": "Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing",
          "documentType": "Notice",
          "publicationDate": "2026-11-18",
          "publicationDatePrecision": "civil-day",
          "agencies": [
            "Food and Drug Administration",
            "Health and Human Services Department"
          ],
          "abstract": "The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of new drug application (NDA) 206679 for Flolipid suspension, 20 milligrams (mg)/5 milliliters (mL) and 40 mg/5 mL and is announcing an opportunity for the NDA holder, Salerno Pharmaceuticals, 2431 East 61st St., Suite 300, Tulsa, OK 74136, to request a hearing on this proposal. The basis for the proposal is that Salerno Pharmaceuticals has repeatedly failed to file required annual reports for NDA 206679.",
          "commentsCloseOn": "2027-01-19",
          "commentDeadlineFieldRequested": true,
          "effectiveOn": null,
          "sourceAction": "Notice.",
          "federalRegisterCitation": "91 FR 74176",
          "docketIds": [
            "Docket No FDA-2026-N-9703"
          ],
          "regulationIdNumbers": [],
          "cfrReferences": [],
          "correctionOf": null,
          "corrections": [],
          "source": {
            "originalApiUrl": "https://www.federalregister.gov/api/v1/documents.json?conditions%5Bpublication_date%5D%5Bgte%5D=2026-11-11&conditions%5Bpublication_date%5D%5Blte%5D=2026-11-18&per_page=100&page=2&order=newest&fields%5B%5D=document_number&fields%5B%5D=title&fields%5B%5D=type&fields%5B%5D=abstract&fields%5B%5D=html_url&fields%5B%5D=publication_date&fields%5B%5D=agencies&fields%5B%5D=comments_close_on&fields%5B%5D=effective_on&fields%5B%5D=action&fields%5B%5D=citation&fields%5B%5D=regulation_id_numbers&fields%5B%5D=cfr_references&fields%5B%5D=docket_ids&fields%5B%5D=correction_of&fields%5B%5D=corrections",
            "originalResponseDigest": "sha256:fb91d36264aee08859627c1d71539c3f821c6068c3cda7b5054d11754d39ea11",
            "originalResponseUri": "ni:///sha-256;-5HTYmSu4IhZYnwdcVOcP4IcYGjDzae1BU0RdU056hE",
            "normalizedLotDigest": "sha256:c1ba8a0c023141d5d3c1b019f3ffad3d0414462174eeeb08ff1d19f2d47784f6",
            "observedAt": "2026-11-18T21:09:36.088Z",
            "provider": "https://www.federalregister.gov",
            "publisher": {
              "name": "Office of the Federal Register",
              "source": "https://www.federalregister.gov/reader-aids/developer-resources/rest-api",
              "reproduction": "https://www.archives.gov/federal-register/faqs",
              "officialNotice": "The source Federal Register edition, not this derived JSON, is authoritative. No government endorsement."
            },
            "evidenceClass": "source-dated government metadata, independently replayable from original HTTP bytes held by the source acquisition run"
          }
        }
      },
      "time": {
        "asserted": "2026-11-18T21:09:36.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid",
        "sourceDigest": "sha256:fb91d36264aee08859627c1d71539c3f821c6068c3cda7b5054d11754d39ea11"
      },
      "status": "unverified"
    },
    {
      "id": "editorial-standing",
      "proposition": {
        "predicate": "editorial-standing",
        "object": "source metadata; editorial acceptance pending"
      },
      "time": {
        "asserted": "2026-11-18T21:09:36.088Z"
      },
      "force": "quotes",
      "provenance": {
        "witness": "https://www.federalregister.gov",
        "method": "quoted collector metadata from an original HTTP response",
        "citation": "https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid",
        "sourceDigest": "sha256:fb91d36264aee08859627c1d71539c3f821c6068c3cda7b5054d11754d39ea11"
      },
      "status": "unverified"
    }
  ]
}
